

Riad Salem

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2272305/publications.pdf>

Version: 2024-02-01

456
papers

29,483
citations

3515

90
h-index

6454

157
g-index

464
all docs

464
docs citations

464
times ranked

12540
citing authors

#	ARTICLE	IF	CITATIONS
1	North American Practice-Based Recommendations for Transjugular Intrahepatic Portosystemic Shunts in Portal Hypertension. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1636-1662.e36.	2.4	95
2	Quality measures in HCC care by the Practice Metrics Committee of the American Association for the Study of Liver Diseases. <i>Hepatology</i> , 2022, 75, 1289-1299.	3.6	26
3	BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. <i>Journal of Hepatology</i> , 2022, 76, 681-693.	1.8	1,495
4	Radioembolization with chemotherapy for liver-dominant colorectal cancer: Analysis of patient subgroups in the EPOCH trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 115-115.	0.8	0
5	Radioembolization with chemotherapy for liver-dominant colorectal cancer: Time to subsequent treatment and quality of life in the EPOCH trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 114-114.	0.8	0
6	Percutaneous Biliary Neo-anastomosis or Neo-duct Creation Using Radiofrequency Wires. <i>CardioVascular and Interventional Radiology</i> , 2022, 45, 337-343.	0.9	5
7	TARE in Hepatocellular Carcinoma: From the Right to the Left of BCLC. <i>CardioVascular and Interventional Radiology</i> , 2022, 45, 1599-1607.	0.9	21
8	Preoperative portal vein recanalizationâ€“transjugular intrahepatic portosystemic shunt for chronic obliterative portal vein thrombosis: Outcomes following liver transplantation. <i>Hepatology Communications</i> , 2022, 6, 1803-1812.	2.0	5
9	Reply. <i>Hepatology</i> , 2022, 75, 1668-1669.	3.6	0
10	Commentary on Percutaneous Trans-splenic Balloon-Assisted Transjugular Intrahepatic Portosystemic Shunt Placement in Patients with Portal Vein Obliteration for Portal Vein Recanalization: Feasibility, Safety and Effectiveness. <i>CardioVascular and Interventional Radiology</i> , 2022, 45, 703-704.	0.9	1
11	A global evaluation of advanced dosimetry in transarterial radioembolization of hepatocellular carcinoma with Yttrium-90: the TARGET study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 3340-3352.	3.3	30
12	Conversion to resection post radioembolization in patients with HCC: recommendations from a multidisciplinary working group. <i>Hpb</i> , 2022, 24, 1007-1018.	0.1	8
13	Transarterial Radioembolization Versus Systemic Treatment for Hepatocellular Carcinoma with Macrovascular Invasion: Analysis of the U.S. National Cancer Database. <i>Journal of Nuclear Medicine</i> , 2022, 63, 57-58.	2.8	1
14	Yttrium-90 for colorectal liver metastasis - the promising role of radiation segmentectomy as an alternative local cure. <i>International Journal of Hyperthermia</i> , 2022, 39, 620-626.	1.1	6
15	Primary retrograde urinary drainage using image and endoscopy guidance via urostomies. <i>Clinical Radiology</i> , 2022, , .	0.5	1
16	Abstract No. 243 Treatment Timing and Overall Survival of Liver-Dominant Metastatic Colorectal Cancer Patients Treated with Glass Transarterial Radioembolization: Analyses from the EPOCH Trial. <i>Journal of Vascular and Interventional Radiology</i> , 2022, 33, S112.	0.2	0
17	Abstract No. 228 Single-institution retrospective review of percutaneous transhepatic image and cholangioscopy guided biliary interventions. <i>Journal of Vascular and Interventional Radiology</i> , 2022, 33, S105.	0.2	0
18	Abstract No. 563 Yttrium-90 radiation segmentectomy for neuroendocrine tumor liver metastases. <i>Journal of Vascular and Interventional Radiology</i> , 2022, 33, S210.	0.2	0

#	ARTICLE	IF	CITATIONS
19	Abstract No. 195 Tumor size is an independent risk factor for mortality after yttrium-90 radioembolization for HCC. <i>Journal of Vascular and Interventional Radiology</i> , 2022, 33, S89-S90.	0.2	0
20	Implementation of radiation segmentectomy for early-stage hepatocellular carcinoma. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, , .	3.7	0
21	Yttrium-90 Radioembolization of Unresectable Intrahepatic Cholangiocarcinoma: Long-Term Follow-up for a 136-Patient Cohort. <i>CardioVascular and Interventional Radiology</i> , 2022, 45, 1117-1128.	0.9	10
22	Interventional treatment of hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2022, 77, 1205-1206.	1.8	8
23	Liver Transplantation Following Yttrium-90 Radioembolization: 15-Year Experience in 207-Patient Cohort. <i>Hepatology</i> , 2021, 73, 998-1010.	3.6	62
24	Management of Symptomatic Portal Cavernoma Cholangiopathy With Transplenic Portal Vein Recanalization and Transjugular Intrahepatic Portosystemic Shunt. <i>Hepatology</i> , 2021, 73, 456-459.	3.6	9
25	Systematic Review and Meta-analysis Comparing Prostatic Artery Embolization to Gold-Standard Transurethral Resection of the Prostate for Benign Prostatic Hyperplasia. <i>CardioVascular and Interventional Radiology</i> , 2021, 44, 183-193.	0.9	39
26	Access Site for Visceral Arterial Interventions: Counterpoint—Transfemoral Remains the Way to Go. <i>American Journal of Roentgenology</i> , 2021, 217, 1-2.	1.0	0
27	Radioembolisation with personalised dosimetry: improving outcomes for patients with advanced hepatocellular carcinoma. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 2-3.	3.7	5
28	Percutaneous Ultrasound-Guided Superior and Inferior Mesenteric Vein Access for Portal Vein Recanalization—Transjugular Intrahepatic Portosystemic Shunt: A Case Series. <i>CardioVascular and Interventional Radiology</i> , 2021, 44, 496-499.	0.9	23
29	Correlation of Y90-absorbed radiation dose to pathological necrosis in hepatocellular carcinoma: confirmatory multicenter analysis in 45 explants. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 580-583.	3.3	78
30	Correlation and Agreement of Yttrium-90 Positron Emission Tomography/Computed Tomography with Ex Vivo Radioembolization Microsphere Deposition in the Rabbit VX2 Liver Tumor Model. <i>Journal of Vascular and Interventional Radiology</i> , 2021, 32, 23-32.e1.	0.2	2
31	Safety and Efficacy of Segmental Yttrium-90 Radioembolization for Hepatocellular Carcinoma after Transjugular Intrahepatic Portosystemic Shunt Creation. <i>Journal of Vascular and Interventional Radiology</i> , 2021, 32, 211-219.	0.2	6
32	Does significantly elevated lung shunt fraction (LSF >20%) promote extrahepatic progression in patients with hepatocellular carcinoma treated with radioembolization?. <i>Nuclear Medicine Communications</i> , 2021, 42, 725-731.	0.5	0
33	Lung shunt and lung dose calculation methods for radioembolization treatment planning. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 65, 32-42.	0.4	10
34	Comparing Real World, Personalized, Multidisciplinary Tumor Board Recommendations with BCLC Algorithm: 321-Patient Analysis. <i>CardioVascular and Interventional Radiology</i> , 2021, 44, 1070-1080.	0.9	25
35	Abstract No. 8 Yttrium-90 radioembolization in unresectable intrahepatic cholangiocarcinoma: a 17-year single-institution study. <i>Journal of Vascular and Interventional Radiology</i> , 2021, 32, S5.	0.2	0
36	Abstract No. 71 Outcomes of segmental Yttrium-90 radioembolization in oligometastatic secondary hepatic malignancies. <i>Journal of Vascular and Interventional Radiology</i> , 2021, 32, S31-S32.	0.2	0

#	ARTICLE	IF	CITATIONS
37	Abstract No. 1 – ^a ABSTRACT OF THE YEAR Y90 radioembolization to the prostate gland: proof of concept in a canine model and clinical translation. <i>Journal of Vascular and Interventional Radiology</i> , 2021, 32, S1-S2.	0.2	0
38	ACR – ABS – ACNM – ASTRO – SIR – SNMMI practice parameter for selective internal radiation therapy or radioembolization for treatment of liver malignancies. <i>Brachytherapy</i> , 2021, 20, 497-511.	0.2	5
39	A phase I study of nivolumab (NIVO) in combination with TheraSphere (Yttrium-90) in patients with advanced hepatocellular cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, e16183-e16183.	0.8	8
40	Characterization of response to atezolizumab + A bevacicuzumab versus sorafenib for hepatocellular carcinoma: Results from the IMbrave150 trial. <i>Cancer Medicine</i> , 2021, 10, 5437-5447.	1.3	29
41	Yttrium – 90 Radioembolization for the Treatment of Solitary, Unresectable HCC: The LEGACY Study. <i>Hepatology</i> , 2021, 74, 2342-2352.	3.6	215
42	TIPS for Adults Without Cirrhosis With Chronic Mesenteric Venous Thrombosis and EHPVO Refractory to Standard – of – Care Therapy. <i>Hepatology</i> , 2021, 74, 2735-2744.	3.6	32
43	Yttrium-90 Radioembolization to the Prostate Gland: Proof of Concept in a Canine Model and – Clinical Translation. <i>Journal of Vascular and Interventional Radiology</i> , 2021, 32, 1103-1112.e12.	0.2	11
44	Role of Interventional Radiology in the Management of Acute Cholangitis. <i>Seminars in Interventional Radiology</i> , 2021, 38, 321-329.	0.3	2
45	Review of Use of Y90 as a Bridge to Liver Resection and Transplantation in Hepatocellular Carcinoma. <i>Journal of Gastrointestinal Surgery</i> , 2021, 25, 2690-2699.	0.9	10
46	Reassessment of the lung dose limits for radioembolization. <i>Nuclear Medicine Communications</i> , 2021, 42, 1064-1075.	0.5	9
47	Future Directions of Percutaneous Biliary Interventions. <i>Seminars in Interventional Radiology</i> , 2021, 38, 373-376.	0.3	4
48	Radioembolization With Chemotherapy for Colorectal Liver Metastases: A Randomized, Open-Label, International, Multicenter, Phase III Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 3897-3907.	0.8	59
49	Contemporary Review of Prostate Artery Embolization for the Treatment of Benign Prostatic Hyperplasia. <i>Advances in Clinical Radiology</i> , 2021, 3, 55-62.	0.1	0
50	LBA21 Radioembolization with chemotherapy for colorectal liver metastases: A randomized, open-label, international, multicenter, phase III trial (EPOCH study). <i>Annals of Oncology</i> , 2021, 32, S1295.	0.6	6
51	Image-guided Interventions with Endoscopic Guidance. <i>Advances in Clinical Radiology</i> , 2021, 3, 73-83.	0.1	1
52	Consensus Guidelines for the Definition of Time-to-Event End Points in Image-guided Tumor Ablation: Results of the SIO and DATECAN Initiative. <i>Radiology</i> , 2021, 301, 533-540.	3.6	72
53	Evolution of Radioembolization in Treatment of Hepatocellular Carcinoma: A Pictorial Review. <i>Radiographics</i> , 2021, 41, 1802-1818.	1.4	33
54	Post-embolization outcomes of splenic artery pseudoaneurysms: A single-center experience. <i>Clinical Imaging</i> , 2021, 80, 160-166.	0.8	5

#	ARTICLE	IF	CITATIONS
55	International recommendations for personalised selective internal radiation therapy of primary and metastatic liver diseases with yttrium-90 resin microspheres. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 1570-1584.	3.3	140
56	Extrahepatic Applications of Yttrium-90 Radioembolization. <i>Seminars in Interventional Radiology</i> , 2021, 38, 479-481.	0.3	2
57	Contemporary Algorithm for the Management of Hepatocellular Carcinoma in 2021: The Northwestern Approach. <i>Seminars in Interventional Radiology</i> , 2021, 38, 432-437.	0.3	3
58	Trans-cervical thoracic duct embolization for post-surgical left Chylothorax in a patient with multifocal lymphatic malformations. <i>CVIR Endovascular</i> , 2021, 4, 73.	0.4	0
59	Radiation Lobectomy: An Overview of Concept and Applications, Technical Considerations, Outcomes. <i>Seminars in Interventional Radiology</i> , 2021, 38, 419-424.	0.3	3
60	Yttrium-90 Radioembolization in the VX2 Rabbit Model: Radiation Safety and Factors Influencing Delivery Efficiency. <i>Journal of Vascular and Interventional Radiology</i> , 2021, 32, 1569-1574.e11.	0.2	0
61	Hepatic Arterial Infusion Chemotherapy for Large Hepatocellular Carcinoma: Ready for Prime Time?. <i>Journal of Clinical Oncology</i> , 2021, , JCO2102392.	0.8	3
62	Safety and efficacy of radioembolization with glass microspheres in hepatocellular carcinoma patients with elevated lung shunt fraction: analysis of a 103-patient cohort. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 807-815.	3.3	12
63	Quality of Life after Radioembolization for Hepatocellular Carcinoma Using a Digital Patient-Reported Outcome Tool. <i>Journal of Vascular and Interventional Radiology</i> , 2020, 31, 311-314.e1.	0.2	9
64	Development of Research Agenda in Prostate Artery Embolization: Summary of Society of Interventional Radiology Consensus Panel. <i>Journal of Vascular and Interventional Radiology</i> , 2020, 31, 108-113.	0.2	1
65	Endovascular Management of Acquired Hepatic Arterial "Portal Venous Malformations. <i>CardioVascular and Interventional Radiology</i> , 2020, 43, 466-477.	0.9	2
66	Percutaneous Access of the Modified Hutson Loop for Retrograde Cholangiography, Endoscopy, and Biliary Interventions. <i>Journal of Vascular and Interventional Radiology</i> , 2020, 31, 2113-2120.e1.	0.2	11
67	The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Pancreatic Neuroendocrine Tumors. <i>Pancreas</i> , 2020, 49, 863-881.	0.5	88
68	4:03 PM Abstract No. 324 Survival comparison of patients undergoing elective transjugular intrahepatic portosystemic shunt creation with intermediate and high Model End Stage Liver Disease scores. <i>Journal of Vascular and Interventional Radiology</i> , 2020, 31, S147-S148.	0.2	0
69	3:54 PM Abstract No. 143 Segmental radioembolization for hepatocellular carcinoma is safe and effective after transjugular intrahepatic portosystemic shunt. <i>Journal of Vascular and Interventional Radiology</i> , 2020, 31, S67-S68.	0.2	0
70	Abstract No. 716 Long-term outcomes of Yttrium-90 radioembolization for hepatocellular carcinoma due to underlying non-alcoholic steatohepatitis. <i>Journal of Vascular and Interventional Radiology</i> , 2020, 31, S308.	0.2	0
71	Contemporary Techniques and Applications of Radioembolization in Patients with Hepatocellular Carcinoma. <i>Advances in Clinical Radiology</i> , 2020, 2, 113-125.	0.1	2
72	3:36 PM Abstract No. 26 Longitudinal study of progression patterns of hepatocellular carcinoma patients undergoing Y90 radiation segmentectomy. <i>Journal of Vascular and Interventional Radiology</i> , 2020, 31, S15-S16.	0.2	0

#	ARTICLE	IF	CITATIONS
73	3:36 PM Abstract No. 141 Radioembolization for recurrent hepatocellular carcinoma after liver transplant: a multicenter exploratory analysis. <i>Journal of Vascular and Interventional Radiology</i> , 2020, 31, S66.	0.2	0
74	Excimer Laser Sheath-Assisted Retrieval of "Closed-Cell" Design Inferior Vena Cava Filters. <i>Journal of the American Heart Association</i> , 2020, 9, e017240.	1.6	5
75	Yttrium-90 Portal Vein Radioembolization in Sprague-Dawley Rats: Dose-Dependent Imaging and Pathological Changes in Normal Liver. <i>CardioVascular and Interventional Radiology</i> , 2020, 43, 1925-1935.	0.9	2
76	Guidelines for Management of Urgent Symptoms in Patients with Cholangiocarcinoma and Biliary Stents or Catheters Using the Modified RAND/UCLA Delphi Process. <i>Cancers</i> , 2020, 12, 2375.	1.7	2
77	Feasibility of Combination Intra-arterial Yttrium-90 and Irinotecan Microspheres in the VX2 Rabbit Model. <i>CardioVascular and Interventional Radiology</i> , 2020, 43, 1528-1537.	0.9	5
78	Observing Durable Responses and a Prolonged Survival Tail in Advanced Hepatocellular Carcinoma with Portal Vein Invasion Treated with Y90 Radioembolization. <i>CardioVascular and Interventional Radiology</i> , 2020, 43, 1423-1424.	0.9	3
79	Management of primary hepatic malignancies during the COVID-19 pandemic: recommendations for risk mitigation from a multidisciplinary perspective. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 765-775.	3.7	33
80	Streamlining radioembolization in UNOS T1/T2 hepatocellular carcinoma by eliminating lung shunt estimation. <i>Journal of Hepatology</i> , 2020, 72, 1151-1158.	1.8	32
81	Toxicity and Survival of Hepatocellular Carcinoma Patients with Hepatitis B Infection Treated with Yttrium-90 Radioembolization: An Updated 15-Year Study. <i>Journal of Vascular and Interventional Radiology</i> , 2020, 31, 401-408.e1.	0.2	6
82	Adverse Events Related to Partial Splenic Embolization for the Treatment of Hypersplenism: A Systematic Review. <i>Journal of Vascular and Interventional Radiology</i> , 2020, 31, 1118-1131.e6.	0.2	20
83	Yttrium-90 Radioembolization and Tumor Hypoxia: Gas-challenge BOLD Imaging in the VX2 Rabbit Model of Hepatocellular Carcinoma. <i>Academic Radiology</i> , 2020, 28, 849-858.	1.3	6
84	3:00 PM Abstract No. 273 Device-specific adverse event rates of retrievable inferior vena cava filters after 90 days: a systematic review and network meta-analysis. <i>Journal of Vascular and Interventional Radiology</i> , 2020, 31, S123.	0.2	0
85	4:03 PM Abstract No. 144 Toxicity and survival outcomes of segmental radioembolization in hepatocellular carcinoma patients with baseline hyperbilirubinemia. <i>Journal of Vascular and Interventional Radiology</i> , 2020, 31, S68.	0.2	0
86	03:27 PM Abstract No. 251 Post-embolization outcomes of splenic artery aneurysms in cirrhotic and non-cirrhotic patients. <i>Journal of Vascular and Interventional Radiology</i> , 2019, 30, S112.	0.2	0
87	Contemporary Systematic Review of Health-Related Quality of Life Outcomes in Locoregional Therapies for Hepatocellular Carcinoma. <i>Journal of Vascular and Interventional Radiology</i> , 2019, 30, 1924-1933.e2.	0.2	15
88	Recent Developments and Therapeutic Strategies against Hepatocellular Carcinoma. <i>Cancer Research</i> , 2019, 79, 4326-4330.	0.4	99
89	Single-session inferior vena cava filter removal, recanalization, and endovenous reconstruction for chronic ilio caval thrombosis. <i>Journal of Vascular Surgery: Venous and Lymphatic Disorders</i> , 2019, 7, 176-183.	0.9	15
90	Prognostic Role of Albumin, Bilirubin, and ALBI Scores: Analysis of 1000 Patients with Hepatocellular Carcinoma Undergoing Radioembolization. <i>Cancers</i> , 2019, 11, 879.	1.7	43

#	ARTICLE	IF	CITATIONS
91	Prostate Artery Embolization. <i>Seminars in Interventional Radiology</i> , 2019, 36, 142-148.	0.3	3
92	03:09 PM Abstract No. 190 Risk factors for ilio caval thrombosis in 1582 inferior vena cava filter-bearing patients. <i>Journal of Vascular and Interventional Radiology</i> , 2019, 30, S86.	0.2	0
93	Clinical and dosimetric considerations for Y90: recommendations from an international multidisciplinary working group. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1695-1704.	3.3	104
94	03:18 PM Abstract No. 171 Predictors of survival after transjugular intrahepatic portosystemic shunt (TIPS) creation with covered stents. <i>Journal of Vascular and Interventional Radiology</i> , 2019, 30, S78.	0.2	0
95	Abstract No. 534 Radioembolization for infiltrative hepatocellular carcinoma: analysis of 183-patient cohort. <i>Journal of Vascular and Interventional Radiology</i> , 2019, 30, S231-S232.	0.2	2
96	03:27 PM Abstract No. 231 Retrospective longitudinal study of long survivors of hepatocellular carcinoma patients with malignant portal vein thrombosis treated with radioembolization: an intention to treat analysis. <i>Journal of Vascular and Interventional Radiology</i> , 2019, 30, S104.	0.2	0
97	Technical Aspects and Practical Approach Toward Same-Day Y90 Radioembolization in the Management of Hepatocellular Carcinoma. <i>Techniques in Vascular and Interventional Radiology</i> , 2019, 22, 93-99.	0.4	13
98	Prognosticating Survival in Hepatocellular Carcinoma with Elevated Baseline Alpha-fetoprotein Treated with Radioembolization Using a Novel Laboratory Scoring System: Initial Development and Validation. <i>CardioVascular and Interventional Radiology</i> , 2019, 42, 700-711.	0.9	5
99	Percutaneous management of malignant biliary disease. <i>Journal of Surgical Oncology</i> , 2019, 120, 45-56.	0.8	17
100	Society of Interventional Radiology Multisociety Consensus Position Statement on Prostatic Artery Embolization for Treatment of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: From the Society of Interventional Radiology, the Cardiovascular and Interventional Radiological Society of Europe, Soci�t� Fran�saise de Radiologie, and the British Society of Interventional Radiology. <i>Journal of Vascular and Interventional Radiology</i> , 2019, 30, 627-637.e1.	0.2	80
101	Neoadjuvant Radiation Lobectomy As an Alternative to Portal Vein Embolization in Hepatocellular Carcinoma. <i>Seminars in Nuclear Medicine</i> , 2019, 49, 197-203.	2.5	28
102	Current knowledge in pathophysiology and management of Budd-Chiari syndrome and non-cirrhotic non-tumoral splanchnic vein thrombosis. <i>Journal of Hepatology</i> , 2019, 71, 175-199.	1.8	80
103	Cost-Effectiveness of a Guided Peripherally Inserted Central Catheter Placement System: A Single-Center Cohort Study. <i>Journal of Vascular and Interventional Radiology</i> , 2019, 30, 709-714.	0.2	15
104	Modified Radiation Lobectomy: An Evolving Paradigm to Convert Patients to Liver Resection Candidacy. <i>Seminars in Interventional Radiology</i> , 2019, 36, 343-348.	0.3	17
105	Laboratory and Imaging Prognostic Indicators following Arterial Locoregional Therapies for Hepatocellular Carcinoma Survival. <i>Journal of Vascular and Interventional Radiology</i> , 2019, 30, 1893-1894.	0.2	0
106	Is hepatectomy safe following Yttrium-90 therapy? A multi-institutional international experience. <i>Hpb</i> , 2019, 21, 1520-1526.	0.1	12
107	MR imaging findings of the prostate gland following prostate artery embolization: results from a prospective phase 2 study. <i>Abdominal Radiology</i> , 2019, 44, 713-722.	1.0	13
108	TheraSphere Yttrium-90 Glass Microspheres Combined With Chemotherapy Versus Chemotherapy Alone in Second-Line Treatment of Patients With Metastatic Colorectal Carcinoma of the Liver: Protocol for the EPOCH Phase 3 Randomized Clinical Trial. <i>JMIR Research Protocols</i> , 2019, 8, e11545.	0.5	27

#	ARTICLE	IF	CITATIONS
109	Pickering-Emulsion for Liver Trans-Arterial Chemo-Embolization with Oxaliplatin. CardioVascular and Interventional Radiology, 2018, 41, 781-788.	0.9	28
110	Microwave or radiofrequency ablation: clinically equivalent?. The Lancet Gastroenterology and Hepatology, 2018, 3, 291-292.	3.7	6
111	Radiation Segmentectomy: Potential Curative Therapy for Early Hepatocellular Carcinoma. Radiology, 2018, 287, 1050-1058.	3.6	168
112	¹⁸F-MRI-guided interventional natural killer cell delivery for liver tumor treatment. Cancer Medicine, 2018, 7, 1860-1869.	1.3	23
113	Perceptions of Quality in Interventional Oncology. Journal of Vascular and Interventional Radiology, 2018, 29, 367-372.e1.	0.2	1
114	Response and Overall Survival for Yttrium-90 Radioembolization of Hepatic Sarcoma: A Multicenter Retrospective Study. Journal of Vascular and Interventional Radiology, 2018, 29, 867-873.	0.2	12
115	Development of National Research and Clinical Agendas for Patient-Reported Outcomes in IR: Proceedings from a Multidisciplinary Consensus Panel. Journal of Vascular and Interventional Radiology, 2018, 29, 1-8.	0.2	16
116	Survival Analysis of Advanced HCC Treated with Radioembolization: Comparing Impact of Clinical Performance Status Versus Vascular Invasion/Metastases. CardioVascular and Interventional Radiology, 2018, 41, 260-269.	0.9	17
117	⁹⁰Y Radioembolization for Locally Advanced Hepatocellular Carcinoma with Portal Vein Thrombosis: Long-Term Outcomes in a 185-Patient Cohort. Journal of Nuclear Medicine, 2018, 59, 1042-1048.	2.8	54
118	¹⁸F-FDG PET Biomarkers Help Detect Early Metabolic Response to Irreversible Electroporation and Predict Therapeutic Outcomes in a Rat Liver Tumor Model. Radiology, 2018, 287, 137-145.	3.6	8
119	Institutional decision to adopt Y90 as primary treatment for hepatocellular carcinoma informed by a 1,000-patient 15-year experience. Hepatology, 2018, 68, 1429-1440.	3.6	174
120	Pictorial essay: imaging findings following Y90 radiation segmentectomy for hepatocellular carcinoma. Abdominal Radiology, 2018, 43, 1723-1738.	1.0	25
121	Pretransplant Intra-arterial Liver-Directed Therapy Does Not Increase the Risk of Hepatic Arterial Complications in Liver Transplantation: A Single-Center 10-Year Experience. CardioVascular and Interventional Radiology, 2018, 41, 231-238.	0.9	10
122	Radioembolization for hepatocellular carcinoma: Statistical confirmation of improved survival in responders by landmark analyses. Hepatology, 2018, 67, 873-883.	3.6	41
123	Radioembolization in Advanced Hepatocellular Carcinoma. Journal of Clinical Oncology, 2018, 36, 1898-1901.	0.8	8
124	Abstract No. 549 A score combining imaging response and laboratory prognosticators: survival predictability for hepatocellular carcinoma. Journal of Vascular and Interventional Radiology, 2018, 29, S230.	0.2	0
125	Outcomes of Surgical Resection after Radioembolization for Hepatocellular Carcinoma. Journal of Vascular and Interventional Radiology, 2018, 29, 1502-1510.e1.	0.2	65
126	Abstract No. 546 Patterns of extrahepatic spread in hepatocellular carcinoma patients with portal vein thrombosis treated with radioembolization. Journal of Vascular and Interventional Radiology, 2018, 29, S229.	0.2	1

#	ARTICLE	IF	CITATIONS
127	Clinical Case Panel: Treatment Alternatives for Inoperable Hepatocellular Carcinoma. Seminars in Radiation Oncology, 2018, 28, 295-308.	1.0	4
128	Radioembolization Super Survivors: Extended Survival in Non-operative Hepatocellular Carcinoma. CardioVascular and Interventional Radiology, 2018, 41, 1557-1565.	0.9	20
129	Prostate Artery Embolization for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: Results From a Prospective FDA-Approved Investigational Device Exemption Study. Urology, 2018, 120, 205-210.	0.5	43
130	4:20 PM Abstract No. 432 Prospective single-center investigational device exemption study of prostate artery embolization for lower urinary tract symptoms. Journal of Vascular and Interventional Radiology, 2018, 29, S9.	0.2	1
131	3:00 PM Abstract No. 81 Radioembolization for hepatocellular carcinoma patients with portal vein thrombosis: a single-center 14-year experience. Journal of Vascular and Interventional Radiology, 2018, 29, S38-S39.	0.2	0
132	3:18 PM Abstract No. 83 Radiation segmentectomy vs. radiofrequency ablation in early stage hepatocellular carcinoma. Journal of Vascular and Interventional Radiology, 2018, 29, S39-S40.	0.2	1
133	3:45 PM Abstract No. 86 Improved post-transplant outcomes in patients achieving pathological necrosis following radioembolization of hepatocellular carcinoma. Journal of Vascular and Interventional Radiology, 2018, 29, S40-S41.	0.2	0
134	Transarterial Radioembolization (TARE)., 2018, , 389-396.		1
135	Abstract No. 630 Cost and positioning of ultrasound and electrocardiogram-guided PICCs. Journal of Vascular and Interventional Radiology, 2018, 29, S262.	0.2	1
136	Intra-Arterial TheraSphere Yttrium-90 Glass Microspheres in the Treatment of Patients With Unresectable Hepatocellular Carcinoma: Protocol for the STOP-HCC Phase 3 Randomized Controlled Trial. JMIR Research Protocols, 2018, 7, e11234.	0.5	31
137	Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals. Journal of Hepatology, 2017, 66, 1173-1181.	1.8	135
138	Comparison of the Adverse Event Profile of TheraSphere® with SIR-Spheres® for the Treatment of Unresectable Hepatocellular Carcinoma: A Systematic Review. CardioVascular and Interventional Radiology, 2017, 40, 1033-1043.	0.9	39
139	Reply. Gastroenterology, 2017, 152, 1628-1629.	0.6	1
140	JOURNAL CLUB: Four-Dimensional Flow MRI-Based Splenic Flow Index for Predicting Cirrhosis-Associated Hypersplenism. American Journal of Roentgenology, 2017, 209, 46-54.	1.0	14
141	Defining Prolonged Dwell Time: When Are Advanced Inferior Vena Cava Filter Retrieval Techniques Necessary?. Circulation: Cardiovascular Interventions, 2017, 10, .	1.4	39
142	Comparative study of post-transplant outcomes in hepatocellular carcinoma patients treated with chemoembolization or radioembolization. European Journal of Radiology, 2017, 93, 100-106.	1.2	30
143	The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine Tumors. Pancreas, 2017, 46, 707-714.	0.5	241
144	Surgical resection following radioembolization for hepatocellular carcinoma. Journal of Vascular and Interventional Radiology, 2017, 28, S122.	0.2	1

#	ARTICLE	IF	CITATIONS
145	Indicators of Lung Shunt Fraction Determined by Technetium-99m Macroaggregated Albumin in Patients with Hepatocellular Carcinoma. CardioVascular and Interventional Radiology, 2017, 40, 1213-1222.	0.9	10
146	Analysis of the RENAL and mRENAL Scores and the Relative Importance of Their Components in the Prediction of Complications and Local Progression after Percutaneous Renal Cryoablation. Journal of Vascular and Interventional Radiology, 2017, 28, 860-867.	0.2	27
147	Response by Desai et al to Letter Regarding Article, "Defining Prolonged Dwell Time: When Are Advanced Inferior Vena Cava Filter Retrieval Techniques Necessary? An Analysis in 762 Procedures" Circulation: Cardiovascular Interventions, 2017, 10, .	1.4	5
148	Pretransplantation Portal Vein Recanalization and Transjugular Intrahepatic Portosystemic Shunt Creation for Chronic Portal Vein Thrombosis: Final Analysis of a 61-Patient Cohort. Journal of Vascular and Interventional Radiology, 2017, 28, 1714-1721.e2.	0.2	101
149	Reminiscing on Remnants: Imaging of Meckel Diverticulum and Its Complications in Adults. American Journal of Roentgenology, 2017, 209, W287-W296.	1.0	24
150	Fluoroscopic Radiation Exposure in Chemoembolization and Radioembolization: Results from a Prospective Randomized Study. Journal of Vascular and Interventional Radiology, 2017, 28, 1272-1273.	0.2	4
151	Immuno-oncology and Its Opportunities for Interventional Radiologists: Immune Checkpoint Inhibition and Potential Synergies with Interventional Oncology Procedures. Journal of Vascular and Interventional Radiology, 2017, 28, 1487-1494.	0.2	33
152	Interventional radiology in the management of the liver transplant patient. Liver Transplantation, 2017, 23, 1328-1341.	1.3	15
153	Clinical outcomes of Y90 radioembolization for recurrent hepatocellular carcinoma following curative resection. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 2195-2202.	3.3	17
154	Retrievable IVC Filters: Comprehensive Review of Device-related Complications and Advanced Retrieval Techniques. Radiographics, 2017, 37, 1236-1245.	1.4	56
155	Long-Term Hepatotoxicity of Yttrium-90 Radioembolization as Treatment of Metastatic Neuroendocrine Tumor to the Liver. Journal of Vascular and Interventional Radiology, 2017, 28, 1520-1526.	0.2	57
156	Quality Improvement Guidelines for Transarterial Chemoembolization and Embolization of Hepatic Malignancy. Journal of Vascular and Interventional Radiology, 2017, 28, 1210-1223.e3.	0.2	103
157	Radioembolization of Hepatic Malignancies: Background, Quality Improvement Guidelines, and Future Directions. Journal of Vascular and Interventional Radiology, 2017, 28, 1-15.	0.2	107
158	Validation of the Hong Kong Liver Cancer Staging System in Determining Prognosis of the North American Patients Following Intra-arterial Therapy. Clinical Gastroenterology and Hepatology, 2017, 15, 746-755.e4.	2.4	33
159	Embolotherapy for Neuroendocrine Tumor Liver Metastases: Prognostic Factors for Hepatic Progression-Free Survival and Overall Survival. CardioVascular and Interventional Radiology, 2017, 40, 69-80.	0.9	81
160	Radioembolization for liver tumors. , 2017, , 1417-1425.e2.		1
161	Cancer Care at Times of Crisis and War: The Syrian Example. Journal of Global Oncology, 2017, 3, 338-345.	0.5	39
162	Making the Case: Intra-arterial Therapy for Less Common Metastases. Seminars in Interventional Radiology, 2017, 34, 132-139.	0.3	12

#	ARTICLE	IF	CITATIONS
163	New Developments in Interventional Oncology. Cancer Journal (Sudbury, Mass), 2016, 22, 373-380.	1.0	11
164	The Direct and Indirect Costs of Ultrasound-Guided Peripherally Inserted Central Catheter Repositioning at a Large Academic Medical Center. , 2016, 21, 230-236.		4
165	Noncirrhotic complete obliterative portal vein thrombosis: Novel management using transâ€splanic transjugular intrahepatic portosystemic shunt with portal vein recanalization. Hepatology, 2016, 63, 1387-1390.	3.6	40
166	Portal Vein Recanalization and Transjugular Intrahepatic Portosystemic Shunt Creation for Chronic Portal Vein Thrombosis: Technical Considerations. Techniques in Vascular and Interventional Radiology, 2016, 19, 52-60.	0.4	78
167	Risk factors for high lung shunt fraction in patients with hepatocellular carcinoma being evaluated for yttrium-90 radioembolization. Journal of Vascular and Interventional Radiology, 2016, 27, S67.	0.2	0
168	Single- versus Triple-Drug Chemoembolization for Hepatocellular Carcinoma: Comparing Outcomes by Toxicity, Imaging Response, and Survival. Journal of Vascular and Interventional Radiology, 2016, 27, 1279-1287.	0.2	14
169	Transarterial Radioembolization with Yttrium-90 for the Treatment of Hepatocellular Carcinoma. Advances in Therapy, 2016, 33, 699-714.	1.3	123
170	Radioembolization as a Treatment Strategy for Metastatic Colorectal Cancer to the Liver: What Can We Learn from the SIRFLOX Trial?. Current Treatment Options in Oncology, 2016, 17, 26.	1.3	20
171	A Dedicated Inferior Vena Cava Filter Service Line: How to Optimize Your Practice. Seminars in Interventional Radiology, 2016, 33, 105-108.	0.3	15
172	The Utility of Unilobar Technetium-99m Macroaggregated Albumin to Predict Pulmonary Toxicity In Bilobar Hepatocellular Carcinoma prior to Yttrium-90 Radioembolization. Journal of Vascular and Interventional Radiology, 2016, 27, 1453-1456.	0.2	7
173	Renal Cell Carcinoma Metastatic to the Liver: Early Response Assessment after Intraarterial Therapy Using 3D Quantitative Tumor Enhancement Analysis. Translational Oncology, 2016, 9, 377-383.	1.7	10
174	Locoregional Therapies for Primary and Secondary Hepatic Malignancies. Cancer Treatment and Research, 2016, 168, 233-256.	0.2	2
175	Angiogenic Response following Radioembolization: Results from a Randomized Pilot Study of Yttrium-90 with or without Sorafenib. Journal of Vascular and Interventional Radiology, 2016, 27, 1329-1336.	0.2	20
176	Current Guidelines for the Diagnosis and Management of Hepatocellular Carcinoma: A Comparative Review. American Journal of Roentgenology, 2016, 207, W88-W98.	1.0	33
177	Yttrium-90 Radioembolization for Breast Cancer Liver Metastases. Journal of Vascular and Interventional Radiology, 2016, 27, 1316-1319.	0.2	14
178	Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients WithÂHepatocellular Carcinoma. Gastroenterology, 2016, 151, 1155-1163.e2.	0.6	498
179	The impact of clinical factor on dosimetry in radioembolisation. Clinical and Translational Imaging, 2016, 4, 225-227.	1.1	2
180	The Role of Four-Dimensional Flow MR Imaging in the Diagnosis and Treatment of a Splenic Arteriovenous Fistula. Journal of Vascular and Interventional Radiology, 2016, 27, 1736-1738.e1.	0.2	1

#	ARTICLE	IF	CITATIONS
181	Same-day 90Y radioembolization: implementing a new treatment paradigm. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 2353-2359.	3.3	51
182	Single-Center Experience Using AngioVac with Extracorporeal Bypass for Mechanical Thrombectomy of Atrial and Central Vein Thrombi. <i>Journal of Vascular and Interventional Radiology</i> , 2016, 27, 723-729.e1.	0.2	34
183	Independent Analysis of Albumin-Bilirubin Grade in a 765-Patient Cohort Treated with Transarterial Locoregional Therapy for Hepatocellular Carcinoma. <i>Journal of Vascular and Interventional Radiology</i> , 2016, 27, 795-802.	0.2	64
184	Reply. <i>Hepatology</i> , 2016, 64, 1375-1376.	3.6	0
185	Assessment of non-surgical versus surgical therapy for localized hepatocellular carcinoma. <i>Journal of Surgical Oncology</i> , 2016, 113, 175-180.	0.8	14
186	⁹⁰ Y radiation lobectomy: Outcomes following surgical resection in patients with hepatic tumors and small future liver remnant volumes. <i>Journal of Surgical Oncology</i> , 2016, 114, 99-105.	0.8	89
187	Percutaneous Cryoablation for the Treatment of Primary and Metastatic Lung Tumors: Identification of Risk Factors for Recurrence and Major Complications. <i>Journal of Vascular and Interventional Radiology</i> , 2016, 27, 1371-1379.	0.2	41
188	⁹⁰ Y Radioembolization of Colorectal Hepatic Metastases Using Glass Microspheres: Safety and Survival Outcomes from a 531-Patient Multicenter Study. <i>Journal of Nuclear Medicine</i> , 2016, 57, 665-671.	2.8	79
189	Yttrium-90 Radioembolization for Hepatocellular Carcinoma. <i>Seminars in Nuclear Medicine</i> , 2016, 46, 105-108.	2.5	14
190	Hepatic imaging following intra-arterial embolotherapy. <i>Abdominal Radiology</i> , 2016, 41, 600-616.	1.0	30
191	Transcatheter Therapy for Hepatic Malignancy: Standardization of Terminology and Reporting Criteria. <i>Journal of Vascular and Interventional Radiology</i> , 2016, 27, 457-473.	0.2	98
192	Commentary on: "Occupational radiation exposure of medical staff performing 90Y-loaded microsphere radioembolization". <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 822-823.	3.3	1
193	Threshold for Enhancement in Treated Hepatocellular Carcinoma on MDCT: Effect on Necrosis Quantification. <i>American Journal of Roentgenology</i> , 2016, 206, 536-543.	1.0	7
194	Types of Research Bias Encountered in IR. <i>Journal of Vascular and Interventional Radiology</i> , 2016, 27, 546-550.	0.2	4
195	Treatment of Liver Tumors with Lipiodol TACE: Technical Recommendations from Experts Opinion. <i>CardioVascular and Interventional Radiology</i> , 2016, 39, 334-343.	0.9	198
196	Role of hepatic intra-arterial therapies in metastatic neuroendocrine tumours (NET): guidelines from the NET-Liver-Metastases Consensus Conference. <i>Hpb</i> , 2015, 17, 29-37.	0.1	153
197	Reproducibility of mRECIST in assessing response to transarterial radioembolization therapy in hepatocellular carcinoma. <i>Hepatology</i> , 2015, 62, 1111-1121.	3.6	51
198	Downstaging: Looking for answers, generating more questions?. <i>Liver Transplantation</i> , 2015, 21, 1117-1119.	1.3	2

#	ARTICLE	IF	CITATIONS
199	Pretransplant Portal Vein Recanalizationâ€”Transjugular Intrahepatic Portosystemic Shunt in Patients With Complete Obliterative Portal Vein Thrombosis. <i>Transplantation</i> , 2015, 99, 2347-2355.	0.5	117
200	Transarterial approaches to primary and secondary hepatic malignancies. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 481-489.	12.5	37
201	Reply. <i>Hepatology</i> , 2015, 61, 407-407.	3.6	4
202	Can volumetric ADC measurement help predict response to Y90 radioembolization in HCC?. <i>Abdominal Imaging</i> , 2015, 40, 1471-1480.	2.0	20
203	Portal Vein Recanalizationâ€”Transjugular Intrahepatic Portosystemic Shunt Using the Transsplenic Approach to Achieve Transplant Candidacy in Patients with Chronic Portal Vein Thrombosis. <i>Journal of Vascular and Interventional Radiology</i> , 2015, 26, 499-506.	0.2	85
204	Yttrium-90 Radioembolization is a Viable Treatment Option for Unresectable, Chemorefractory Colorectal Cancer Liver Metastases: Further Evidence in Support of a New Treatment Paradigm. <i>Annals of Surgical Oncology</i> , 2015, 22, 706-707.	0.7	11
205	A Comparison of Retrievability: Celect versus Option Filter. <i>Journal of Vascular and Interventional Radiology</i> , 2015, 26, 865-869.	0.2	20
206	Prostatic Arterial Embolization versus Transurethral Resection of the Prostate for Benign Prostatic Hyperplasia. <i>Radiology</i> , 2015, 276, 310-312.	3.6	22
207	Thermal ablation of colorectal liver metastases: a position paper by an international panel of ablation experts, the interventional oncology sans frontiÃ¨res meeting 2013. <i>European Radiology</i> , 2015, 25, 3438-3454.	2.3	247
208	Locoregional Therapy of Hepatocellular Carcinoma. <i>Clinics in Liver Disease</i> , 2015, 19, 401-420.	1.0	28
209	Y90 radioembolization of colorectal cancer liver metastases: response assessment by contrast-enhanced computed tomography with or without PET-CT guidance. <i>Clinical Imaging</i> , 2015, 39, 454-462.	0.8	3
210	Effect of TIPS placement on portal and splanchnic arterial blood flow in 4-dimensional flow MRI. <i>European Radiology</i> , 2015, 25, 2634-2640.	2.3	36
211	Intraarterial Hepatic SPECT/CT Imaging Using 99mTc-Macroaggregated Albumin in Preparation for Radioembolization. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1157-1162.	2.8	21
212	Retrieval of Inferior Vena Cava Filters With Prolonged Dwell Time. <i>JAMA Internal Medicine</i> , 2015, 175, 1572.	2.6	36
213	Gastric injury from 90Y to left hepatic lobe tumors adjacent to the stomach: fact or fiction?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 2038-2044.	3.3	11
214	Hepatic Trauma, Surgery, and Liver-Directed Therapy. , 2015, , 1706-1736.		0
215	Side Effects of Yttrium-90 Radioembolization. <i>Frontiers in Oncology</i> , 2014, 4, 198.	1.3	134
216	Transarterial Chemoembolization and Radioembolization. <i>Seminars in Liver Disease</i> , 2014, 34, 435-443.	1.8	71

#	ARTICLE	IF	CITATIONS
217	Perfusion Reduction at Transcatheter Intraarterial Perfusion MR Imaging: A Promising Intra-procedural Biomarker to Predict Transplant-Free Survival during Chemoembolization of Hepatocellular Carcinoma. <i>Radiology</i> , 2014, 272, 587-597.	3.6	17
218	Unresectable solitary hepatocellular carcinoma not amenable to radiofrequency ablation: Multicenter radiology-pathology correlation and survival of radiation segmentectomy. <i>Hepatology</i> , 2014, 60, 192-201.	3.6	237
219	Seven-Tesla Magnetic Resonance Imaging Accurately Quantifies Intratumoral Uptake of Therapeutic Nanoparticles in the McA Rat Model of Hepatocellular Carcinoma. <i>Investigative Radiology</i> , 2014, 49, 87-92.	3.5	5
220	Hepatic yttrium-90 radioembolization for metastatic melanoma. <i>Melanoma Research</i> , 2014, 24, 244-251.	0.6	23
221	Ethanol Embolotherapy of Vascular Malformations: Clinical Outcomes at a Single Center. <i>Journal of Vascular and Interventional Radiology</i> , 2014, 25, 206-213.	0.2	48
222	Tumor Growth Kinetics Versus RECIST to Assess Response to Locoregional Therapy in Breast Cancer Liver Metastases. <i>Academic Radiology</i> , 2014, 21, 950-957.	1.3	11
223	Prospective randomized pilot study of Y90+ ¹⁷⁷ Lu sorafenib as bridge to transplantation in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2014, 61, 309-317.	1.8	80
224	Localized Hyperthermia with Iron Oxide- ⁶⁴ Cu Doped Yttrium Microparticles: Steps toward Image-Guided Thermoradiotherapy in Liver Cancer. <i>Journal of Vascular and Interventional Radiology</i> , 2014, 25, 397-404.	0.2	18
225	Outpatient Single-Session Yttrium-90 Glass Microsphere Radioembolization. <i>Journal of Vascular and Interventional Radiology</i> , 2014, 25, 266-270.	0.2	53
226	Sustained safety and efficacy of extended-shelf-life 90Y glass microspheres: long-term follow-up in a 134-patient cohort. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 486-493.	3.3	21
227	Recommendations for management of patients with neuroendocrine liver metastases. <i>Lancet Oncology</i> , 2014, 15, e8-e21.	5.1	413
228	Image-Guided Tumor Ablation: Standardization of Terminology and Reporting Criteria—A 10-Year Update. <i>Journal of Vascular and Interventional Radiology</i> , 2014, 25, 1691-1705.e4.	0.2	365
229	Transarterial Chemoembolization and Yttrium-90 for Liver Cancer and Other Lesions. <i>Clinics in Liver Disease</i> , 2014, 18, 877-890.	1.0	10
230	Yttrium-90 Radioembolization Stops Progression of Targeted Breast Cancer Liver Metastases after Failed Chemotherapy. <i>Journal of Vascular and Interventional Radiology</i> , 2014, 25, 1523-1532.e2.	0.2	55
231	Reply to "Hepatic Radioembolization as a True Single-Session Treatment". <i>Journal of Vascular and Interventional Radiology</i> , 2014, 25, 1144-1146.	0.2	5
232	Yttrium-90 radioembolization for hepatocellular carcinoma in hepatitis B: commentary on a 103-patient Asian cohort. <i>Hepatology International</i> , 2014, 8, 304-307.	1.9	0
233	In Reply to Putnam. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 90, 473-474.	0.4	0
234	Twelve-year experience of radioembolization for colorectal hepatic metastases in 214 patients: survival by era and chemotherapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 1861-1869.	3.3	80

#	ARTICLE	IF	CITATIONS
235	Chemoradiation of Hepatic Malignancies: Prospective, Phase 1 Study of Full-Dose Capecitabine With Escalating Doses of Yttrium-90 Radioembolization. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 88, 1025-1031.	0.4	43
236	MR Imaging Enables Measurement of Therapeutic Nanoparticle Uptake in Rat N1-S1 Liver Tumors after Nanoablation. <i>Journal of Vascular and Interventional Radiology</i> , 2014, 25, 1288-1294.	0.2	3
237	Comparative Study of Staging Systems for Hepatocellular Carcinoma in 428 Patients Treated with Radioembolization. <i>Journal of Vascular and Interventional Radiology</i> , 2014, 25, 1056-1066.	0.2	20
238	Rationale of transcatheter intra-arterial therapies of hepatic cancers. <i>Hepatic Oncology</i> , 2014, 1, 285-291.	4.2	2
239	Imaging tumor response following liver-directed intra-arterial therapy. <i>Abdominal Imaging</i> , 2013, 38, 1286-1299.	2.0	28
240	Radioembolization for hepatocellular carcinoma with portal vein thrombosis: Impact of liver function on systemic treatment options at disease progression. <i>Journal of Hepatology</i> , 2013, 58, 73-80.	1.8	110
241	Treatment of Hepatocellular Carcinoma Combining Sorafenib and Transarterial Locoregional Therapy: State of the Science. <i>Journal of Vascular and Interventional Radiology</i> , 2013, 24, 1123-1134.	0.2	33
242	Intra-arterial Therapy for Advanced Intrahepatic Cholangiocarcinoma: A Multi-institutional Analysis. <i>Annals of Surgical Oncology</i> , 2013, 20, 3779-3786.	0.7	134
243	Image-Guided Local Delivery Strategies Enhance Therapeutic Nanoparticle Uptake in Solid Tumors. <i>ACS Nano</i> , 2013, 7, 7724-7733.	7.3	50
244	Positron Emission Tomography/CT after Yttrium-90 Radioembolization: Current and Future Applications. <i>Journal of Vascular and Interventional Radiology</i> , 2013, 24, 1153-1155.	0.2	7
245	Cancer Concepts and Principles: Primer for the Interventional Oncologistâ€™Part I. <i>Journal of Vascular and Interventional Radiology</i> , 2013, 24, 1157-1164.	0.2	28
246	Phase 2 trial of concurrent bevacizumab and transhepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. <i>Cancer</i> , 2013, 119, 1042-1049.	2.0	38
247	Embolc Therapies. , 2013, , 101-113.		0
248	Radioembolisation for liver metastases: Results from a prospective 151 patient multi-institutional phase II study. <i>European Journal of Cancer</i> , 2013, 49, 3122-3130.	1.3	82
249	Radiation lobectomy: Time-dependent analysis of future liver remnant volume in unresectable liver cancer as a bridge to resection. <i>Journal of Hepatology</i> , 2013, 59, 1029-1036.	1.8	215
250	Chemoembolization and Radioembolization for Hepatocellular Carcinoma. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 604-611.	2.4	83
251	Prophylactic Embolization of the Gastroduodenal and Right Gastric Arteries Is Not Routinely Necessary before Radioembolization with Glass Microspheres. <i>Journal of Vascular and Interventional Radiology</i> , 2013, 24, 1743-1745.	0.2	39
252	Radioembolization of Renal Cell Carcinoma Using Yttrium-90 Microspheres. <i>Journal of Vascular and Interventional Radiology</i> , 2013, 24, 298-300.	0.2	14

#	ARTICLE	IF	CITATIONS
253	Portal vein thromboembolism/TIPS: a novel pre-liver transplant interventional approach to rendering the untransplantable patient transplant-ready. <i>Journal of Vascular and Interventional Radiology</i> , 2013, 24, S61.	0.2	3
254	Increased Quality of Life Among Hepatocellular Carcinoma Patients Treated With Radioembolization, Compared With Chemoembolization. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 1358-1365.e1.	2.4	220
255	In Regard to Yu et al. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 86, 211.	0.4	1
256	Yttrium-90 Radioembolization for the Treatment of Unresectable Hepatocellular Carcinoma in Patients with Transjugular Intrahepatic Portosystemic Shunts. <i>Journal of Vascular and Interventional Radiology</i> , 2013, 24, 74-80.	0.2	21
257	Response assessment methodologies in hepatocellular carcinoma: Complexities in the era of local and systemic treatments. <i>Journal of Hepatology</i> , 2013, 58, 1260-1262.	1.8	16
258	The role of potentially retrievable inferior vena cava filters in high-risk patients undergoing joint arthroplasty. <i>Journal of Vascular and Interventional Radiology</i> , 2013, 24, S85.	0.2	0
259	Cancer Concepts and Principles: Primer for the Interventional Oncologistâ€”Part II. <i>Journal of Vascular and Interventional Radiology</i> , 2013, 24, 1167-1188.	0.2	26
260	Optional or Permanent: Clinical Factors that Optimize Inferior Vena Cava Filter Utilization. <i>Journal of Vascular and Interventional Radiology</i> , 2013, 24, 35-40.	0.2	31
261	Prospective Evaluation of Patients with Early-/Intermediate-stage Hepatocellular Carcinoma with Disease Progression Following Arterial Locoregional Therapy: Candidacy for Systemic Treatment or Clinical Trials. <i>Journal of Vascular and Interventional Radiology</i> , 2013, 24, 1189-1197.e2.	0.2	18
262	Yttrium-90 Radioembolization for Intrahepatic Cholangiocarcinoma: Safety, Response, and Survival Analysis. <i>Journal of Vascular and Interventional Radiology</i> , 2013, 24, 1227-1234.	0.2	194
263	Locoregional surgical and interventional therapies for advanced colorectal liver metastasis: expert consensus statement. <i>Hpb</i> , 2013, 15, 131-133.	0.1	4
264	Combining Transarterial Chemoembolization With Radiofrequency Ablation for Hepatocellular Carcinoma: One Step Forward?. <i>Journal of Clinical Oncology</i> , 2013, 31, 406-408.	0.8	21
265	Yttrium 90 radioembolization for the treatment of hepatocellular carcinoma: Biological lessons, current challenges, and clinical perspectives. <i>Hepatology</i> , 2013, 58, 2188-2197.	3.6	154
266	Minimally Invasive Therapies for Hepatic Malignancy. <i>Current Problems in Surgery</i> , 2013, 50, 146-179.	0.6	7
267	Assessment of Liver Tumor Response to Therapy: Role of Quantitative Imaging. <i>Radiographics</i> , 2013, 33, 1781-1800.	1.4	85
268	Radiological-pathological analysis of WHO, RECIST, EASL, mRECIST and DWI: Imaging analysis from a prospective randomized trial of Y90 \pm sorafenib. <i>Hepatology</i> , 2013, 58, 1655-1666.	3.6	66
269	Yttrium 90 Microspheres for the Treatment of Hepatocellular Carcinoma. <i>Recent Results in Cancer Research</i> , 2013, 190, 207-224.	1.8	28
270	Chemoembolization and Radioembolization in the Treatment of Primary Liver Cancers. , 2013, , 327-338.		0

#	ARTICLE	IF	CITATIONS
271	A phase II trial of y-90 radioembolization in patients with progressive hepatic metastases from neuroendocrine carcinoma at an NCI-designated comprehensive cancer center.. Journal of Clinical Oncology, 2013, 31, 312-312.	0.8	0
272	Radioembolization for the Treatment of Liver Tumors. American Journal of Clinical Oncology: Cancer Clinical Trials, 2012, 35, 91-99.	0.6	118
273	Integrating Radioembolization With Chemotherapy in the Treatment Paradigm for Unresectable Colorectal Liver Metastases. American Journal of Clinical Oncology: Cancer Clinical Trials, 2012, 35, 293-301.	0.6	21
274	Integrating Radioembolization (90Y Microspheres) Into Current Treatment Options for Liver Tumors. American Journal of Clinical Oncology: Cancer Clinical Trials, 2012, 35, 81-90.	0.6	22
275	Radioembolization in the Treatment of Unresectable Liver Tumors. American Journal of Clinical Oncology: Cancer Clinical Trials, 2012, 35, 167-177.	0.6	40
276	Locoregional Chemoembolic Delivery: Prediction With Transcatheter Intraarterial Perfusion MRI. American Journal of Roentgenology, 2012, 198, 1196-1202.	1.0	7
277	Integrating Radioembolization into the Treatment Paradigm for Metastatic Neuroendocrine Tumors in the Liver. American Journal of Clinical Oncology: Cancer Clinical Trials, 2012, 35, 393-398.	0.6	31
278	Radiation Pneumonitis Following Yttrium-90 Radioembolization: Case Report and Literature Review. Journal of Vascular and Interventional Radiology, 2012, 23, 669-674.	0.2	78
279	Chemoembolization and Radioembolization for Metastatic Disease to the Liver: Available Data and Future Studies. Current Treatment Options in Oncology, 2012, 13, 403-415.	1.3	38
280	Radioembolization for Neuroendocrine Liver Metastases: Safety, Imaging, and Long-Term Outcomes. International Journal of Radiation Oncology Biology Physics, 2012, 83, 887-894.	0.4	137
281	Optimizing IVC Filter Utilization: A Prospective Study of the Impact of Interventional Radiologist Consultation. Journal of the American College of Radiology, 2012, 9, 657-660.	0.9	12
282	MDCT Necrosis Quantification in the Assessment of Hepatocellular Carcinoma Response to Yttrium 90 Radioembolization Therapy. Academic Radiology, 2012, 19, 48-54.	1.3	29
283	Fibrin Cap Disruption: An Adjunctive Technique for Inferior Vena Cava Filter Retrieval. Journal of Vascular and Interventional Radiology, 2012, 23, 1233-1235.	0.2	17
284	Abstract No. 165: Survival in patients with hepatic colorectal metastases: 10 year experience in 180 patients treated with Yttrium-90 radioembolization. Journal of Vascular and Interventional Radiology, 2012, 23, S69.	0.2	0
285	Quality Improvement Guidelines for Transhepatic Arterial Chemoembolization, Embolization, and Chemotherapeutic Infusion for Hepatic Malignancy. Journal of Vascular and Interventional Radiology, 2012, 23, 287-294.	0.2	152
286	Alpha-fetoprotein response correlates with EASL response and survival in solitary hepatocellular carcinoma treated with transarterial therapies: A subgroup analysis. Journal of Hepatology, 2012, 56, 1112-1120.	1.8	82
287	Radioembolization: Clinical Results Hepatocellular Carcinoma. Medical Radiology, 2012, , 379-383.	0.0	0
288	Abstract No. 240: Assessing clinical and imaging patterns of progression following locoregional therapy for hepatocellular carcinoma: candidature for systemic therapy or clinical trials. Journal of Vascular and Interventional Radiology, 2012, 23, S98-S99.	0.2	0

#	ARTICLE	IF	CITATIONS
289	Abstract No. 51 Optional or permanent? Clinical factors that optimize IVC filter utilization. Journal of Vascular and Interventional Radiology, 2012, 23, S24.	0.2	0
290	Treating and Downstaging Hepatocellular Carcinoma in the Caudate Lobe with Yttrium-90 Radioembolization. CardioVascular and Interventional Radiology, 2012, 35, 1094-1101.	0.9	30
291	Radioembolization for liver tumors. , 2012, , 1362-1369.e2.		0
292	Patient Selection and Activity Planning Guide for Selective Internal Radiotherapy With Yttrium-90 Resin Microspheres. International Journal of Radiation Oncology Biology Physics, 2012, 82, 401-407.	0.4	190
293	Extrahepatic metastases occur in a minority of hepatocellular carcinoma patients treated with locoregional therapies: Analyzing patterns of progression in 285 patients. Hepatology, 2012, 55, 1432-1442.	3.6	64
294	Abstract No. 18: The timing of electroporation after delivery of therapeutic nanoparticles affects drug uptake in VX2 tumors. Journal of Vascular and Interventional Radiology, 2011, 22, S11-S12.	0.2	1
295	Research Reporting Standards for Radioembolization of Hepatic Malignancies. Journal of Vascular and Interventional Radiology, 2011, 22, 265-278.	0.2	185
296	Abstract No. 204: Safety and efficacy of extended-shelf-life Yttrium-90 glass microspheres: Validating study from a 134 patient cohort. Journal of Vascular and Interventional Radiology, 2011, 22, S88.	0.2	0
297	Intra-procedural Transcatheter Intra-arterial Perfusion MRI as a Predictor of Tumor Response to Chemoembolization for Hepatocellular Carcinoma. Academic Radiology, 2011, 18, 828-836.	1.3	17
298	Invited Commentary. Journal of Vascular and Interventional Radiology, 2011, 22, 1362-1363.	0.2	1
299	Abstract No. 182: Quality of life assessment of patients treated with Yttrium-90 or transarterial chemoembolization: A comparative study using the fact-hep. Journal of Vascular and Interventional Radiology, 2011, 22, S79.	0.2	2
300	Radioembolization Results in Longer Time-to-Progression and Reduced Toxicity Compared With Chemoembolization in Patients With Hepatocellular Carcinoma. Gastroenterology, 2011, 140, 497-507.e2.	0.6	566
301	Radiographic Response to Locoregional Therapy in Hepatocellular Carcinoma Predicts Patient Survival Times. Gastroenterology, 2011, 141, 526-535.e2.	0.6	148
302	Recommendations of the American Association of Physicists in Medicine on dosimetry, imaging, and quality assurance procedures for ⁹⁰ Y microsphere brachytherapy in the treatment of hepatic malignancies. Medical Physics, 2011, 38, 4824-4845.	1.6	208
303	Role of the EASL, RECIST, and WHO response guidelines alone or in combination for hepatocellular carcinoma: Radiologic pathologic correlation. Journal of Hepatology, 2011, 54, 695-704.	1.8	140
304	Imaging characteristics following ⁹⁰ yttrium microsphere treatment for unresectable liver cancer. Journal of Medical Imaging and Radiation Oncology, 2011, 55, 111-118.	0.9	36
305	Radioembolization for Hepatocellular Carcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2011, 34, 422-431.	0.6	91
306	General Selection Criteria of Patients for Radioembolization of Liver Tumors. American Journal of Clinical Oncology: Cancer Clinical Trials, 2011, 34, 337-341.	0.6	72

#	ARTICLE	IF	CITATIONS
307	Radioembolization for Primary and Metastatic Liver Cancer. <i>Seminars in Radiation Oncology</i> , 2011, 21, 294-302.	1.0	78
308	Internal Pair Production of ⁹⁰ Y Permits Hepatic Localization of Microspheres Using Routine PET: Proof of Concept. <i>Journal of Nuclear Medicine</i> , 2011, 52, 72-76.	2.8	119
309	Radiologic Assessment of Response to Therapy: Comparison of RECIST Versions 1.1 and 1.0. <i>Radiographics</i> , 2011, 31, 2093-2105.	1.4	73
310	Four-dimensional transcatheter intraarterial perfusion MRI monitoring of radiofrequency ablation of rabbit VX2 liver tumors. <i>Journal of Magnetic Resonance Imaging</i> , 2011, 34, 563-569.	1.9	8
311	Radiation Segmentectomy: A Novel Approach to Increase Safety and Efficacy of Radioembolization. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 79, 163-171.	0.4	199
312	In Reply to Dr. Kao et al.. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 80, 1280-1281.	0.4	1
313	Response to Treatment Series: Part 2, Tumor Response Assessment Using New and Conventional Criteria. <i>American Journal of Roentgenology</i> , 2011, 197, 18-27.	1.0	66
314	Quantitative 4D Transcatheter Intraarterial Perfusion MRI for Standardizing Angiographic Chemoembolization Endpoints. <i>American Journal of Roentgenology</i> , 2011, 197, 1237-1243.	1.0	15
315	Hepatic Radioembolization Complicated by Gastrointestinal Ulceration. <i>Seminars in Interventional Radiology</i> , 2011, 28, 240-245.	0.3	21
316	Chemoembolization Endpoints: Effect on Survival Among Patients With Hepatocellular Carcinoma. <i>American Journal of Roentgenology</i> , 2011, 196, 919-928.	1.0	61
317	Hepatic Radioembolization Complicated by Abscess. <i>Seminars in Interventional Radiology</i> , 2011, 28, 222-225.	0.3	13
318	Transcatheter Intraarterial Therapies: Rationale and Overview. <i>Radiology</i> , 2011, 259, 641-657.	3.6	206
319	Radioembolization of unresectable hepatic metastases using yttrium-90 microspheres in heavily pretreated colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2011, 29, 559-559.	0.8	0
320	Radioembolization (Yttrium-90 Microspheres) for Primary and Metastatic Hepatic Malignancies. <i>Cancer Journal (Sudbury, Mass)</i> , 2010, 16, 163-175.	1.0	80
321	Diffusion-weighted magnetic resonance imaging to predict response of hepatocellular carcinoma to chemoembolization. <i>World Journal of Gastroenterology</i> , 2010, 16, 3161.	1.4	44
322	Yttrium-90 radioembolization in the management of liver tumors: expanding the global experience. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 451-452.	3.3	4
323	Hepatic Abscess After Yttrium-90 Radioembolization for Islet-Cell Tumor Hepatic Metastasis. <i>Cardiovascular and Interventional Radiology</i> , 2010, 33, 650-653.	0.9	16
324	Radiologic Pathologic Correlation of Hepatocellular Carcinoma Treated with Chemoembolization. <i>Cardiovascular and Interventional Radiology</i> , 2010, 33, 1143-1152.	0.9	82

#	ARTICLE	IF	CITATIONS
325	A Simple Fluoroscopic Approach to Percutaneous Transgastric Cystgastrostomy with Internalized Drainage Catheter for Treatment of Pancreatic Pseudocysts: Report of Two Cases. <i>Digestive Diseases and Sciences</i> , 2010, 55, 523-528.	1.1	3
326	Transjugular Intrahepatic Portosystemic Shunt with Thrombectomy for the Treatment of Portal Vein Thrombosis After Liver Transplantation. <i>Digestive Diseases and Sciences</i> , 2010, 55, 529-534.	1.1	19
327	Yttrium-90 Radioembolization in the Management of Liver Malignancies. <i>Seminars in Oncology</i> , 2010, 37, 94-101.	0.8	18
328	Quantitative 4D transcatheter intraarterial perfusion MRI for monitoring chemoembolization of hepatocellular carcinoma. <i>Journal of Magnetic Resonance Imaging</i> , 2010, 31, 1106-1116.	1.9	22
329	Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus statement. <i>Hpb</i> , 2010, 12, 313-320.	0.1	68
330	Chemoembolization for Hepatocellular Carcinoma: Comprehensive Imaging and Survival Analysis in a 172-Patient Cohort. <i>Radiology</i> , 2010, 255, 955-965.	3.6	141
331	Imaging Response in the Primary Index Lesion and Clinical Outcomes Following Transarterial Locoregional Therapy for Hepatocellular Carcinoma. <i>JAMA - Journal of the American Medical Association</i> , 2010, 303, 1062.	3.8	170
332	Fluoro-2-Deoxy- ¹⁸ F-Glucose Positron Emission Tomography/Computed Tomography Predicts Extrahepatic Metastatic Potential of Colorectal Metastasis: A Practical Guide for Yttrium-90 Microsphere Liver-Directed Therapy. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2010, 25, 233-236.	0.7	5
333	Reply to S. Kilickap et al. <i>Journal of Clinical Oncology</i> , 2010, 28, e100-e100.	0.8	1
334	Does Multidetector CT Attenuation Change in Colon Cancer Liver Metastases Treated with ⁹⁰ Y Help Predict Metabolic Activity at FDG PET?. <i>Radiology</i> , 2010, 255, 164-172.	3.6	31
335	Yttrium-90 Radioembolization for Liver Malignancies: Prognostic Factors Associated with Survival. <i>Journal of Vascular and Interventional Radiology</i> , 2010, 21, 90-95.	0.2	42
336	Safety of Yttrium-90 Microsphere Radioembolization in Patients with Biliary Obstruction. <i>Journal of Vascular and Interventional Radiology</i> , 2010, 21, 1213-1218.	0.2	14
337	Abstract No. 70 [Cope]: Image-guided nanoembolization as a novel local therapy for pancreatic cancer: Feasibility in an animal model. <i>Journal of Vascular and Interventional Radiology</i> , 2010, 21, S28.	0.2	1
338	Agreement between Competing Imaging Measures of Response of Hepatocellular Carcinoma to Yttrium-90 Radioembolization. <i>Journal of Vascular and Interventional Radiology</i> , 2010, 21, 515-521.	0.2	38
339	Radioembolization for Hepatocellular Carcinoma Using Yttrium-90 Microspheres: A Comprehensive Report of Long-term Outcomes. <i>Gastroenterology</i> , 2010, 138, 52-64.	0.6	925
340	Improving Inferior Vena Cava Filter Retrieval Rates: Impact of a Dedicated Inferior Vena Cava Filter Clinic. <i>Journal of Vascular and Interventional Radiology</i> , 2010, 21, 1847-1851.	0.2	172
341	Direct Hepatic Artery Puncture for Transarterial Therapy in Liver Cancer. <i>Journal of Vascular and Interventional Radiology</i> , 2010, 21, 394-399.	0.2	7
342	Dose-escalating study of yttrium 90 microspheres with capecitabine for intrahepatic cholangiocarcinoma or metastatic disease to the liver.. <i>Journal of Clinical Oncology</i> , 2010, 28, TPS216-TPS216.	0.8	1

#	ARTICLE	IF	CITATIONS
343	Functional magnetic resonance imaging in an animal model of pancreatic cancer. <i>World Journal of Gastroenterology</i> , 2010, 16, 3292.	1.4	4
344	Liver Tumors: Metastases. , 2010, , 197-203.		1
345	Alpha-Fetoprotein Response After Locoregional Therapy for Hepatocellular Carcinoma: Oncologic Marker of Radiologic Response, Progression, and Survival. <i>Journal of Clinical Oncology</i> , 2009, 27, 5734-5742.	0.8	199
346	A Comparative Analysis of Transarterial Downstaging for Hepatocellular Carcinoma: Chemoembolization Versus Radioembolization. <i>American Journal of Transplantation</i> , 2009, 9, 1920-1928.	2.6	540
347	Radiologic-pathologic correlation of hepatocellular carcinoma treated with internal radiation using yttrium-90 microspheres. <i>Hepatology</i> , 2009, 49, 1185-1193.	3.6	229
348	Reply:. <i>Hepatology</i> , 2009, 50, 653-653.	3.6	2
349	Radioembolization of colorectal hepatic metastases using yttrium-90 microspheres. <i>Cancer</i> , 2009, 115, 1849-1858.	2.0	164
350	Internal radioembolization for colorectal carcinoma liver metastases. <i>Current Colorectal Cancer Reports</i> , 2009, 5, 93-98.	1.0	0
351	Radiologic findings following Y90 radioembolization for primary liver malignancies. <i>Abdominal Imaging</i> , 2009, 34, 566-581.	2.0	88
352	Treatment Parameters and Outcome in 680 Treatments of Internal Radiation With Resin 90Y-Microspheres for Unresectable Hepatic Tumors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 74, 1494-1500.	0.4	238
353	Radiation Lobectomy: Preliminary Findings of Hepatic Volumetric Response to Lobar Yttrium-90 Radioembolization. <i>Annals of Surgical Oncology</i> , 2009, 16, 1587-1596.	0.7	207
354	Optimization of Radioembolic Effect with Extended-shelf-life Yttrium-90 Microspheres: Results from a Pilot Study. <i>Journal of Vascular and Interventional Radiology</i> , 2009, 20, 1557-1563.	0.2	31
355	Complications Following Radioembolization with Yttrium-90 Microspheres: A Comprehensive Literature Review. <i>Journal of Vascular and Interventional Radiology</i> , 2009, 20, 1121-1130.	0.2	305
356	Transcatheter Therapy for Hepatic Malignancy: Standardization of Terminology and Reporting Criteria. <i>Journal of Vascular and Interventional Radiology</i> , 2009, 20, S425-S434.	0.2	151
357	Development of a VX2 Pancreatic Cancer Model in Rabbits: A Pilot Study. <i>Journal of Vascular and Interventional Radiology</i> , 2009, 20, 1075-1082.	0.2	13
358	The Role of Tumor Vascularity in Predicting Survival after Yttrium-90 Radioembolization for Liver Metastases. <i>Journal of Vascular and Interventional Radiology</i> , 2009, 20, 1564-1569.	0.2	56
359	Neuroendocrine Tumors. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2009, 7, 712-712.	2.3	163
360	Hepatobiliary Cancers. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2009, 7, 350-391.	2.3	719

#	ARTICLE	IF	CITATIONS
361	Minimally Invasive Techniques in Management of Hepatic Neuroendocrine Metastatic Disease. American Journal of Clinical Oncology: Cancer Clinical Trials, 2009, 32, 200-215.	0.6	26
362	Chemoembolization, Radioembolization and Other Novel Intra-arterial Therapies. , 2009, , 124-133.		0
363	Yttrium-90 radioembolization using TheraSphere in the management of primary and secondary liver tumors. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2009, 53, 311-6.	0.4	15
364	Diagnosis and Management of Superior Vena Cava Syndrome. , 2008, , 552-562.		0
365	Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology, 2008, 47, 71-81.	3.6	542
366	Fibrosis, Portal Hypertension, and Hepatic Volume Changes Induced by Intra-arterial Radiotherapy with 90Yttrium Microspheres. Digestive Diseases and Sciences, 2008, 53, 2556-2563.	1.1	132
367	Radiographic Response to Yttrium-90 Radioembolization in Anterior Versus Posterior Liver Segments. CardioVascular and Interventional Radiology, 2008, 31, 1124-1132.	0.9	15
368	Treatment of unresectable cholangiocarcinoma using yttrium-90 microspheres. Cancer, 2008, 113, 2119-2128.	2.0	182
369	Thoracic Duct Embolization: A New Treatment for Massive Leak After Neck Dissection. Laryngoscope, 2008, 118, 680-683.	1.1	42
370	Unresectable Chemorefractory Liver Metastases: Radioembolization with ⁹⁰ Y Microspheres—Safety, Efficacy, and Survival. Radiology, 2008, 247, 507-515.	3.6	207
371	Tumor Response after Yttrium-90 Radioembolization for Hepatocellular Carcinoma: Comparison of Diffusion-weighted Functional MR Imaging with Anatomic MR Imaging. Journal of Vascular and Interventional Radiology, 2008, 19, 1180-1186.	0.2	112
372	Abstract No. 124: Effect of Chemotherapy on Hepatic Vasculature in Patients Undergoing Y-90 Radioembolization for Metastatic Disease. Journal of Vascular and Interventional Radiology, 2008, 19, S48-S49.	0.2	6
373	Vascular Anatomy and Its Implication in Radioembolization. Medical Radiology, 2008, , 29-42.	0.0	2
374	MR Imaging Perfusion Mismatch: A Technique to Verify Successful Targeting of Liver Tumors during Transcatheter Arterial Chemoembolization. Journal of Vascular and Interventional Radiology, 2008, 19, 698-705.	0.2	10
375	Abstract No. 214: Four Dimensional Transcatheter Intra-Arterial Perfusion MRI (4D TRIP-MRI) for Monitoring Hepatic Chemoembolization. Journal of Vascular and Interventional Radiology, 2008, 19, S81-S82.	0.2	0
376	Biliary Sequelae following Radioembolization with Yttrium-90 Microspheres. Journal of Vascular and Interventional Radiology, 2008, 19, 691-697.	0.2	147
377	Comparison of Two Different Methods for Inoculating VX2 Tumors in Rabbit Livers and Hind Limbs. Journal of Vascular and Interventional Radiology, 2008, 19, 931-936.	0.2	54
378	Abstract No. 35: Yttrium 90 Radioembolization for Liver Metastases: Prognostic Factors Associated with Survival. Journal of Vascular and Interventional Radiology, 2008, 19, S15.	0.2	0

#	ARTICLE	IF	CITATIONS
379	Abstract No. 33: Treatment of Neuroendocrine Liver Metastases with 90Y Radioembolization. Journal of Vascular and Interventional Radiology, 2008, 19, S14.	0.2	0
380	Yttrium-90 Microsphere Radioembolotherapy of Hepatic Metastatic Neuroendocrine Carcinomas after Hepatic Arterial Embolization. Journal of Vascular and Interventional Radiology, 2008, 19, 145-151.	0.2	67
381	Four-dimensional Transcatheter Intraarterial Perfusion MR Imaging for Monitoring Chemoembolization of Hepatocellular Carcinoma: Preliminary Results. Journal of Vascular and Interventional Radiology, 2008, 19, 1589-1595.	0.2	24
382	Comparison of Hypoxia-inducible Factor-1 α Expression before and after Transcatheter Arterial Embolization in Rabbit VX2 Liver Tumors. Journal of Vascular and Interventional Radiology, 2008, 19, 1483-1489.	0.2	83
383	Abstract No. 127: Treatment of Cholangiocarcinoma Using 90Y Microspheres: Results from a Pilot Study. Journal of Vascular and Interventional Radiology, 2008, 19, S49-S50.	0.2	0
384	MR Tracking of Iron-labeled Glass Radioembolization Microspheres during Transcatheter Delivery to Rabbit VX2 Liver Tumors: Feasibility Study. Radiology, 2008, 249, 845-854.	3.6	46
385	Radioembolization of Yttrium-90 Microspheres for Hepatic Malignancy. Seminars in Interventional Radiology, 2008, 25, 048-057.	0.3	47
386	Transcatheter Intraarterial Perfusion: MR Monitoring of Chemoembolization for Hepatocellular Carcinoma—Feasibility of Initial Clinical Translation. Radiology, 2008, 246, 964-971.	3.6	48
387	Multimodality Imaging Following ⁹⁰ Y Radioembolization: A Comprehensive Review and Pictorial Essay. Radiographics, 2008, 28, 81-99.	1.4	128
388	Radioembolization with ⁹⁰ Yttrium Microspheres for Colorectal Liver Metastases. , 2008, , 280-289.		0
389	Radioembolization for Unresectable Neuroendocrine Hepatic Metastases Using Resin 90Y-Microspheres: Early Results in 148 Patients. American Journal of Clinical Oncology: Cancer Clinical Trials, 2008, 31, 271-279.	0.6	403
390	Incidence of Radiation Pneumonitis After Hepatic Intra-Arterial Radiotherapy With Yttrium-90 Microspheres Assuming Uniform Lung Distribution. American Journal of Clinical Oncology: Cancer Clinical Trials, 2008, 31, 431-438.	0.6	157
391	90Y Radioembolization for Metastatic Neuroendocrine Liver Tumors. Annals of Surgery, 2008, 247, 1029-1035.	2.1	213
392	Radioembolization : Identifying and Managing Anatomic Variants. Medical Radiology, 2008, , 43-50.	0.0	3
393	Hepatic Trauma and Surgery. , 2008, , 1771-1793.		1
394	SU-GG-T-49: Improved Technique for Determining Y-90 Glass Microsphere Activity Delivered. Medical Physics, 2008, 35, 2737-2737.	1.6	1
395	Radioembolization for the treatment of unresectable hepatocellular carcinoma: A clinical review. World Journal of Gastroenterology, 2008, 14, 1664.	1.4	96
396	Future Directions in Radioembolization. Medical Radiology, 2008, , 147-156.	0.0	0

#	ARTICLE	IF	CITATIONS
397	Radioembolization with Yttrium-90 microspheres: review of an emerging treatment for liver tumors. <i>Future Oncology</i> , 2007, 3, 73-81.	1.1	31
398	Imaging of Hepatocellular Carcinoma After Treatment with Yttrium-90 Microspheres. <i>American Journal of Roentgenology</i> , 2007, 188, 768-775.	1.0	109
399	Response of Liver Metastases After Treatment with Yttrium-90 Microspheres: Role of Size, Necrosis, and PET. <i>American Journal of Roentgenology</i> , 2007, 188, 776-783.	1.0	117
400	Liver Tumors: Monitoring Embolization in Rabbits with VX2 Tumors—Transcatheter Intraarterial First-Pass Perfusion MR Imaging. <i>Radiology</i> , 2007, 245, 130-139.	3.6	45
401	Emerging Approaches in Hepatocellular Carcinoma. <i>Journal of Clinical Gastroenterology</i> , 2007, 41, 839-854.	1.1	15
402	Technical Aspects of Radioembolization with 90Y Microspheres. <i>Techniques in Vascular and Interventional Radiology</i> , 2007, 10, 12-29.	0.4	121
403	Radiation Dose Limits and Liver Toxicities Resulting from Multiple Yttrium-90 Radioembolization Treatments for Hepatocellular Carcinoma. <i>Journal of Vascular and Interventional Radiology</i> , 2007, 18, 1375-1382.	0.2	107
404	A Comparison of Chemoembolization Endpoints Using Angiographic versus Transcatheter Intraarterial Perfusion/MR Imaging Monitoring. <i>Journal of Vascular and Interventional Radiology</i> , 2007, 18, 1249-1257.	0.2	62
405	Comparison of Transcatheter Intraarterial Perfusion MR Imaging and Fluorescent Microsphere Perfusion Measurements during Transcatheter Arterial Embolization of Rabbit Liver Tumors. <i>Journal of Vascular and Interventional Radiology</i> , 2007, 18, 1280-1286.	0.2	16
406	Transcatheter Therapy for Hepatic Malignancy: Standardization of Terminology and Reporting Criteria. <i>Journal of Vascular and Interventional Radiology</i> , 2007, 18, 1469-1478.	0.2	60
407	Reduction of Arteriohepatovenous Shunting by Temporary Balloon Occlusion in Patients Undergoing Radioembolization. <i>Journal of Vascular and Interventional Radiology</i> , 2007, 18, 1310-1314.	0.2	37
408	Effect of Transcatheter Arterial Embolization on Levels of Hypoxia-inducible Factor-1 α in Rabbit VX2 Liver Tumors. <i>Journal of Vascular and Interventional Radiology</i> , 2007, 18, 639-645.	0.2	61
409	Effect of C-arm Angiographic CT on Transcatheter Arterial Chemoembolization of Liver Tumors. <i>Journal of Vascular and Interventional Radiology</i> , 2007, 18, 1305-1309.	0.2	87
410	Radioembolization with 90Y Microspheres: Technical Considerations. <i>Journal of Vascular and Interventional Radiology</i> , 2007, 18, 1460-1461.	0.2	13
411	Gastrointestinal Complications Associated with Hepatic Arterial Yttrium-90 Microsphere Therapy. <i>Journal of Vascular and Interventional Radiology</i> , 2007, 18, 553-561.	0.2	163
412	90Y Radioembolization of Metastatic Breast Cancer to the Liver: Toxicity, Imaging Response, Survival. <i>Journal of Vascular and Interventional Radiology</i> , 2007, 18, 621-628.	0.2	92
413	Recommendations for Radioembolization of Hepatic Malignancies Using Yttrium-90 Microsphere Brachytherapy: A Consensus Panel Report from the Radioembolization Brachytherapy Oncology Consortium. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 68, 13-23.	0.4	625
414	Radioembolization with 90Y Microspheres: Angiographic and Technical Considerations. <i>CardioVascular and Interventional Radiology</i> , 2007, 30, 571-592.	0.9	232

#	ARTICLE	IF	CITATIONS
415	Radioembolization with 90Yttrium Microspheres: A State-of-the-Art Brachytherapy Treatment for Primary and Secondary Liver Malignancies. <i>Journal of Vascular and Interventional Radiology</i> , 2006, 17, 1251-1278.	0.2	619
416	Radioembolization with Yttrium-90 Microspheres: A State-of-the-Art Brachytherapy Treatment for Primary and Secondary Liver Malignancies. <i>Journal of Vascular and Interventional Radiology</i> , 2006, 17, 1571-1593.	0.2	201
417	Radioembolization with 90Yttrium Microspheres: A State-of-the-Art Brachytherapy Treatment for Primary and Secondary Liver Malignancies. <i>Journal of Vascular and Interventional Radiology</i> , 2006, 17, 1425-1439.	0.2	189
418	Diffusion-weighted MR Imaging for Determination of Hepatocellular Carcinoma Response to Yttrium-90 Radioembolization. <i>Journal of Vascular and Interventional Radiology</i> , 2006, 17, 1195-1200.	0.2	111
419	Trans-arterial hepatic radioembolisation of yttrium-90 microspheres. <i>Biomedical Imaging and Intervention Journal</i> , 2006, 2, e43.	0.5	18
420	Multishot Diffusion-Weighted PROPELLER Magnetic Resonance Imaging of the Abdomen. <i>Investigative Radiology</i> , 2006, 41, 769-775.	3.5	85
421	In Vivo Diffusion-Weighted Imaging of Liver Tumor Necrosis in the VX2 Rabbit Model at 1.5 Tesla. <i>Investigative Radiology</i> , 2006, 41, 410-414.	3.5	49
422	Yttrium-90 microspheres for the treatment of hepatocellular carcinoma: A review. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 66, S83-S88.	0.4	71
423	Successful Embolization of Hepatocellular Carcinoma With Yttrium-90 Glass Microspheres Prior to Liver Transplantation. <i>Journal of Gastrointestinal Surgery</i> , 2006, 10, 413-416.	0.9	27
424	Treatment of Unresectable Primary and Metastatic Liver Cancer with Yttrium-90 Microspheres (TheraSphere®): Assessment of Hepatic Arterial Embolization. <i>CardioVascular and Interventional Radiology</i> , 2006, 29, 522-529.	0.9	210
425	Yttrium-90 microspheres (TheraSphere®) treatment of unresectable hepatocellular carcinoma: Downstaging to resection, RFA and bridge to transplantation. <i>Journal of Surgical Oncology</i> , 2006, 94, 572-586.	0.8	297
426	Comparison between intravenous and intraarterial contrast injections for dynamic 3D MRI of liver tumors in the VX2 rabbit model. <i>Journal of Magnetic Resonance Imaging</i> , 2006, 24, 242-247.	1.9	21
427	Yttrium-90 Radioembolization of Hepatocellular Carcinoma and Metastatic Disease to the Liver. <i>Seminars in Interventional Radiology</i> , 2006, 23, 064-072.	0.3	82
428	Regional Yttrium-90 Microsphere Treatment of Surgically Unresectable and Chemotherapy-Refractory Metastatic Liver Carcinoma. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2006, 21, 305-313.	0.7	31
429	Radioactive Microspheres for the Treatment of HCC. , 2006, , 141-148.		1
430	Yttrium-90 Radioembolization for the Treatment of Liver Metastases. , 2006, , 149-161.		0
431	Use of yttrium-90 microspheres (TheraSphere®) in a patient with unresectable hepatocellular carcinoma leading to liver transplantation: A case report. <i>Liver Transplantation</i> , 2005, 11, 1127-1131.	1.3	55
432	Complications of Renal Transplantation. <i>Radiographics</i> , 2005, 25, 1335-1356.	1.4	208

#	ARTICLE	IF	CITATIONS
433	The Effect of Catheter-Directed CT Angiography on Yttrium-90 Radioembolization Treatment of Hepatocellular Carcinoma. <i>Journal of Vascular and Interventional Radiology</i> , 2005, 16, 1085-1091.	0.2	63
434	Primary Failure of Uterine Artery Embolization: Use of Magnetic Resonance Imaging to Select Patients for Repeated Embolization. <i>Journal of Vascular and Interventional Radiology</i> , 2005, 16, 1143-1147.	0.2	25
435	Determination of Optimal Gadolinium Concentration Using SSFP for Catheter-directed Contrast-enhanced Coronary MR Angiography ¹ . <i>Academic Radiology</i> , 2005, 12, 771-775.	1.3	5
436	90Y Microsphere (TheraSphere) Treatment for Unresectable Colorectal Cancer Metastases of the Liver: Response to Treatment at Targeted Doses of 135-150 Gy as Measured by [18F]Fluorodeoxyglucose Positron Emission Tomography and Computed Tomographic Imaging. <i>Journal of Vascular and Interventional Radiology</i> , 2005, 16, 1641-1651.	0.2	162
437	Yttrium 90: Concepts and Principles. <i>Journal of Vascular and Interventional Radiology</i> , 2005, 16, P276-P280.	0.2	2
438	Treatment of Unresectable Hepatocellular Carcinoma with Use of 90Y Microspheres (TheraSphere): Safety, Tumor Response, and Survival. <i>Journal of Vascular and Interventional Radiology</i> , 2005, 16, 1627-1639.	0.2	392
439	Real-time MRI Monitoring of Transcatheter Hepatic Artery Contrast Agent Delivery in Rabbits ¹ . <i>Academic Radiology</i> , 2005, 12, 1342-1350.	1.3	7
440	Reduction of Metastatic Load to Liver after Intraarterial Hepatic Yttrium-90 Radioembolization as Evaluated by [18F]Fluorodeoxyglucose Positron Emission Tomographic Imaging. <i>Journal of Vascular and Interventional Radiology</i> , 2005, 16, 1101-1106.	0.2	82
441	Treatment of Unresectable Hepatocellular Carcinoma with Intrahepatic Yttrium 90 Microspheres: Factors Associated with Liver Toxicities. <i>Journal of Vascular and Interventional Radiology</i> , 2005, 16, 205-213.	0.2	175
442	Feasibility of Blood Oxygenation Level-dependent MR Imaging to Monitor Hepatic Transcatheter Arterial Embolization in Rabbits. <i>Journal of Vascular and Interventional Radiology</i> , 2005, 16, 1523-1528.	0.2	29
443	Angiographic Considerations in Patients Undergoing Liver-directed Therapy. <i>Journal of Vascular and Interventional Radiology</i> , 2005, 16, 911-935.	0.2	237
444	Treatment of Unresectable Hepatocellular Carcinoma with Intrahepatic Yttrium 90 Microspheres: A Risk-Stratification Analysis. <i>Journal of Vascular and Interventional Radiology</i> , 2005, 16, 195-203.	0.2	114
445	Use of Yttrium-90 Glass Microspheres (TheraSphere) for the Treatment of Unresectable Hepatocellular Carcinoma in Patients with Portal Vein Thrombosis. <i>Journal of Vascular and Interventional Radiology</i> , 2004, 15, 335-345.	0.2	201
446	Yttrium-90 microspheres for the treatment of hepatocellular carcinoma. <i>Gastroenterology</i> , 2004, 127, S194-S205.	0.6	332
447	Metabolic response after intraarterial 90Y-glass microsphere treatment for colorectal liver metastases: comparison of quantitative and visual analyses by 18F-FDG PET. <i>Journal of Nuclear Medicine</i> , 2004, 45, 1892-7.	2.8	58
448	Closure of a Ureterocutaneous Fistula with a Covered Stent-Graft. <i>Journal of Vascular and Interventional Radiology</i> , 2003, 14, 793-795.	0.2	10
449	Yttrium-90 Microspheres: Radiation Therapy for Unresectable Liver Cancer. <i>Journal of Vascular and Interventional Radiology</i> , 2002, 13, S223-S229.	0.2	225
450	Radiologically guided percutaneous fine-needle aspiration biopsy of the liver: Retrospective study of 119 cases evaluating diagnostic effectiveness and clinical complications. <i>Diagnostic Cytopathology</i> , 2002, 26, 283-289.	0.5	40

#	ARTICLE	IF	CITATIONS
451	Evaluating ⁹⁰ Y-glass microsphere treatment response of unresectable colorectal liver metastases by [¹⁸ F]FDG PET: a comparison with CT or MRI. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2002, 29, 815-820.	3.3	148
452	Effect of MR Angiography on the Diagnosis and Treatment of Patients with Suspected Renovascular Disease. <i>Journal of Vascular and Interventional Radiology</i> , 2001, 12, 1179-1183.	0.2	3
453	Management of Chylothorax by Percutaneous Catheterization and Embolization of the Thoracic Duct: Prospective Trial. <i>Journal of Vascular and Interventional Radiology</i> , 1999, 10, 1248-1254.	0.2	142
454	Digital Cameras: A Rapid and Inexpensive Means of Transferring Angiographic Images to Referring Clinicians. <i>Journal of Vascular and Interventional Radiology</i> , 1999, 10, 994-995.	0.2	1
455	Principles of radioembolization. , 0, , 44-51.		0
456	⁹⁰ Yttrium radioembolization for hepatocellular carcinoma. , 0, , 128-133.		0